Back to Authors

Hilt, Dana

Mayo Clinic

Lysosomal Therapeutics (United States)

Citations 2

O4‐02‐01: PHASE 2A RANDOMIZED, DOUBLE‐BLIND, PLACEBO‐CONTROLLED TRIAL OF THE HISTONE DEACETYLASE INHIBITOR (HDACI), FRM‐0334, IN ASYMPTOMATIC CARRIERS OF, OR PATIENTS WITH FRONTOTEMPORAL LOBAR DEGENERATION (FTLD) DUE TO, PROGRANULIN GENE MUTATIONS
Boxer, Adam L. , Moebius, Hans J. , Harris, Baruch, Mummery, Catherine, Ber, Isabelle Le , Hannequin, Didier , McGinnis, Scott M., Auriacombe, Sophie, Goodman, Ira , Riordan, Henry, Wisniewski, Gary, Hesterman, Jacob , Patzke, Holger, Koenig, Gerhard, Hilt, Dana, Boeve, Bradley F. , Borroni, Barbara , Swieten, John C. van , Grossman, Murray , Pasquier, Florence , Frisoni, Giovanni B. , Vandenberghe, Rik , ONOFRJ, MARCO C. , Marek, Kenneth

Alzheimer's & Dementia | October 18, 2019 | Volume: 15 | Issue: 7S_Part_23 | Pages: No page available

10.1016/j.jalz.2019.06.4746 Get It